Anixa Biosciences has entered in a license agreement with the Cleveland Clinic to obtain the exclusive, global rights for a new ovarian cancer vaccine technology. “Through this collaboration we are expanding into additional preventive and therapeutic areas and we look forward to seeing the development of this ovarian cancer vaccine,” Vincent Tuohy, PhD, an immunologist at the Cleveland Clinic who has been working on the new vaccine, said in a press release. “Research into cancer therapies…
You must be logged in to read/download the full post.
The post Anixa Enters License Agreement With Cleveland Clinic for Ovarian Cancer Vaccine appeared first on BioNewsFeeds.